|
EJBY, Denmark, April 2, 2024 /PRNewswire/ - - Today Scantox, together with its majority owner Impilo, finalized the acquisition of QPS Neuropharmacology, a leading drug discovery CRO specialized in neurodegenerative, rare diseases and mental disorders. The company, as of today integrated into the Scantox Group as Scantox Neuro, ...
Adnkronos
-
2-4-2024
|
|